Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Daniel Botelho Costa, M.D.

Co-Author

This page shows the publications co-authored by Daniel Costa and Deepa Rangachari.
Connection Strength

12.705
  1. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. J Thorac Oncol. 2019 11; 14(11):1995-2002.
    View in: PubMed
    Score: 0.859
  2. From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer. J Clin Oncol. 2019 10 01; 37(28):2511-2513.
    View in: PubMed
    Score: 0.849
  3. Updated Correlation of 22C3-PD-L1 =50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting. J Thorac Oncol. 2018 05; 13(5):e81-e83.
    View in: PubMed
    Score: 0.787
  4. Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol. 2017 11; 12(11):e175-e177.
    View in: PubMed
    Score: 0.740
  5. Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. Transl Cancer Res. 2017 Feb; 6(Suppl 1):S151-S157.
    View in: PubMed
    Score: 0.722
  6. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 =50% Expression in Lung Adenocarcinoma. J Thorac Oncol. 2017 05; 12(5):878-883.
    View in: PubMed
    Score: 0.720
  7. Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice. Cancer Treat Commun. 2016; 9:41-43.
    View in: PubMed
    Score: 0.694
  8. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015 Apr; 88(1):108-11.
    View in: PubMed
    Score: 0.629
  9. Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. Cancer Treat Commun. 2015; 4:174-181.
    View in: PubMed
    Score: 0.625
  10. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. JAMA Netw Open. 2021 02 01; 4(2):e2037120.
    View in: PubMed
    Score: 0.238
  11. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Oncologist. 2021 04; 26(4):281-287.
    View in: PubMed
    Score: 0.233
  12. The rapidly evolving landscape of biomarker testing in non-small cell lung cancer. Cancer Cytopathol. 2021 03; 129(3):179-181.
    View in: PubMed
    Score: 0.230
  13. Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic? Front Oncol. 2020; 10:1193.
    View in: PubMed
    Score: 0.228
  14. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? J Immunother Cancer. 2020 06; 8(1).
    View in: PubMed
    Score: 0.228
  15. Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer. JTO Clin Res Rep. 2020 Nov 01; 1(4):100071.
    View in: PubMed
    Score: 0.228
  16. Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? Precis Cancer Med. 2020 Jun; 3.
    View in: PubMed
    Score: 0.228
  17. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer. 2021 05; 22(3):e379-e389.
    View in: PubMed
    Score: 0.228
  18. EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors. JTO Clin Res Rep. 2020 Sep; 1(3).
    View in: PubMed
    Score: 0.227
  19. Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2020 May 01; 26(9):2277.
    View in: PubMed
    Score: 0.226
  20. Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer? Transl Lung Cancer Res. 2019 Oct; 8(5):715-722.
    View in: PubMed
    Score: 0.217
  21. Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis. Clin Lung Cancer. 2020 01; 21(1):e6-e9.
    View in: PubMed
    Score: 0.217
  22. Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer. J Thorac Oncol. 2019 02; 14(2):e34-e36.
    View in: PubMed
    Score: 0.207
  23. Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018 09 13; 379(11):1093.
    View in: PubMed
    Score: 0.202
  24. EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2018 12 15; 24(24):6548-6555.
    View in: PubMed
    Score: 0.201
  25. Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. Transl Cancer Res. 2018 Aug; 7(Suppl 7):S779-S786.
    View in: PubMed
    Score: 0.200
  26. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. J Thorac Oncol. 2019 01; 14(1):e1-e3.
    View in: PubMed
    Score: 0.199
  27. Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer. 2018 02; 116:90-95.
    View in: PubMed
    Score: 0.193
  28. Moving more potent and less toxic options to the frontline in the management of advanced lung cancer. J Thorac Dis. 2017 Sep; 9(9):2812-2818.
    View in: PubMed
    Score: 0.188
  29. De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma. Lung Cancer. 2017 12; 114:108-110.
    View in: PubMed
    Score: 0.188
  30. Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies. J Thorac Oncol. 2017 04; 12(4):e35-e36.
    View in: PubMed
    Score: 0.183
  31. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer. 2017 04; 106:17-21.
    View in: PubMed
    Score: 0.180
  32. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lung Cancer. 2016 09; 99:17-22.
    View in: PubMed
    Score: 0.173
  33. EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review. Clin Lung Cancer. 2016 11; 17(6):483-492.
    View in: PubMed
    Score: 0.173
  34. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016 Apr; 10(2):113-29.
    View in: PubMed
    Score: 0.166
  35. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer. 2015 Dec; 90(3):369-74.
    View in: PubMed
    Score: 0.166
  36. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clin Lung Cancer. 2015 Sep; 16(5):e105-9.
    View in: PubMed
    Score: 0.159
  37. De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. Lung Cancer. 2015 Apr; 88(1):70-3.
    View in: PubMed
    Score: 0.157
  38. Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021 Jan; 5:325-332.
    View in: PubMed
    Score: 0.060
  39. Identification of a RAS-activating TMEM87A-RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 08 01; 26(15):4072-4079.
    View in: PubMed
    Score: 0.056
  40. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Lung Cancer. 2020 07; 145:181-185.
    View in: PubMed
    Score: 0.056
  41. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target. Clin Lung Cancer. 2018 09; 19(5):e589-e590.
    View in: PubMed
    Score: 0.049
  42. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 07; 13(7):1037-1042.
    View in: PubMed
    Score: 0.049
  43. Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. Cancer Treat Res Commun. 2018; 15:17-20.
    View in: PubMed
    Score: 0.049
  44. PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? J Am Soc Cytopathol. 2018 May-Jun; 7(3):133-141.
    View in: PubMed
    Score: 0.049
  45. Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis. Clin Lung Cancer. 2017 09; 18(5):e349-e356.
    View in: PubMed
    Score: 0.046
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.